Understanding Richter Transformation: Symptoms, Causes, and Treatment

Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026

Richter transformation (RT) is a rare and aggressive complication where slow-growing chronic lymphocytic leukemia (CLL) transforms into a fast-growing lymphoma. [1] While challenging to treat, new therapies like CAR T-cell therapy and clinical trials are improving the outlook for patients. Early diagnosis through biopsy and specialized imaging is critical for effective management.

Quick Answer

Richter transformation, also known as Richter syndrome, occurs when chronic lymphocytic leukemia (CLL) evolves into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma. [1] [3] It affects about 2% to 10% of CLL patients [1] and causes sudden swollen lymph nodes, fever and rapid weight loss. [1] Treatment includes intensive chemoimmunotherapy, targeted drugs and possibly stem cell transplants.

What the research says

• Outcomes are often poor, but better when CLL was previously untreated. In 204 patients with biopsy-confirmed Richter transformation treated at one center, median overall survival was 12.0 months; patients who had received no prior CLL treatment had a median survival of 46.3 months, versus 7.8 months for those who had been treated (P < 0.001) (Wang et al., Haematologica, 2020) [2].

• Stem cell transplant may help carefully selected patients. In the same series, 24 patients (12%) underwent stem cell transplant (20 autologous and 4 allogeneic) and had a median post-transplant survival of 55.4 months, and the authors concluded that transplant may benefit select patients (Wang et al., Haematologica, 2020) [2].

• Clinical trials are central to care. A review of emerging treatments (BTK, BCL-2, CD79, CD20, PI3K and PD-1 targeted drugs, bispecific T-cell engagers, CAR T-cell therapy and transplant) noted that a clonal relationship to the preceding CLL is found in most cases and is linked to resistance to standard chemoimmunotherapy and inferior survival, and it recommends prioritizing clinical trial enrollment (Rippel et al., Cancers, 2024) [3].

What is Richter transformation and how does it start?

Richter transformation (RT) represents a significant shift in the clinical course of chronic lymphocytic leukemia (CLL). In this rare syndrome, the typically slow-growing CLL cells undergo genetic mutations that cause them to transform into a much more aggressive and fast-growing cancer. For the majority of patients—approximately 95%—the cancer becomes diffuse large B-cell lymphoma (DLBCL), while a smaller subset develops Hodgkin lymphoma. [1]

This complication is relatively rare, impacting between 2 and 10 out of every 100 people living with CLL. [1] Because RT is highly aggressive, identifying the early signs of transformation is essential for adjusting treatment plans and improving patient outcomes. In some cases, the aggressive lymphoma that develops may be genetically unrelated to the original CLL cells, which typically carries a more favorable prognosis. [1]

Feature	Description
Primary Condition	Chronic Lymphocytic Leukemia (CLL)
Transformed State	Aggressive Lymphoma (DLBCL or Hodgkin)
Prevalence in CLL	2% to 10% of patients
Primary Transformation	Diffuse Large B-cell Lymphoma (~95%)
Secondary Transformation	Hodgkin Lymphoma (~5%)

What is the biological basis of Richter transformation?

The exact cause of Richter transformation remains a subject of intense medical research, though genetic instability is a primary factor. Most individuals with the condition exhibit mutations in specific genes that are responsible for preventing tumor formation or regulating cell growth. [1] These genetic changes allow the cancer to bypass normal cellular controls, leading to rapid and uncontrolled tumor expansion.

Current research is focused on identifying the precise triggers for these mutations. By understanding the specific genetic "off-switches" that fail during transformation, researchers hope to develop more targeted therapies that can destroy transformed cells while sparing healthy tissue.

Figure 1: Illustration showing the cellular evolution from slow-growing CLL cells to aggressive, fast-growing lymphoma cells.

What are the sudden symptoms of Richter transformation?

Unlike the gradual progression of CLL, the symptoms of Richter transformation often appear suddenly [1] and with high intensity. These symptoms can occur at any point but frequently emerge within the first few years after a patient begins treatment for CLL. [1] Recognizing these changes early is vital for seeking urgent medical evaluation.

Clinical signs often include:

• Rapidly swelling lymph nodes in the neck, armpits, or groin. [1]

• Significant abdominal pain or a feeling of bloating. [1]

• A sudden loss of appetite and unexplained fatigue. [1]

• "B Symptoms": Fever, night sweats, and rapid, unexplained weight loss. [1]

These "B symptoms" are particularly important as they indicate that the disease has become highly active [1] and requires immediate clinical attention.

How is Richter transformation diagnosed?

When a healthcare provider suspects Richter transformation due to new or worsening symptoms, a definitive diagnosis requires a combination of imaging and tissue analysis. A physical exam may reveal enlarged nodes, but specialized tests are needed to confirm the presence of transformed cancer cells.

The primary diagnostic tools include:

• PET-CT Scan: This imaging test identifies areas of the body with high metabolic activity [1], which often indicates where CLL has evolved into an aggressive lymphoma.

• Biopsy: A tissue sample is taken from the areas showing the highest activity on the PET-CT scan to confirm the transformation under a microscope. [1]

• Genetic Testing: Analysis of the cancer cells to identify specific mutations that may guide targeted treatment options.

Figure 2: Clinical checklist of Richter transformation symptoms and the diagnostic steps required for confirmation.

How is Richter transformation managed and treated?

Treating Richter transformation is complex and depends on the patient's overall health and the specific genetic profile of the transformed cells. [1] The primary goal of treatment is to achieve remission, where no signs or symptoms of the cancer remain. [1]

Standard and New Therapies

Standard treatment often involves a combination of chemotherapy and immunotherapy, such as the R-CHOP regimen for DLBCL. [1] However, because traditional treatments can sometimes be ineffective or highly toxic, many patients are encouraged to participate in clinical trials. [1] [3] These trials provide access to cutting-edge therapies, including:

• CAR T-cell Therapy: A process where a patient's own immune cells are engineered to fight the cancer.

• Targeted Oral Medications: Drugs that precisely attack the weaknesses in cancer cells or boost the immune system's response.

Stem Cell Transplantation

For patients who achieve remission, a stem cell transplant (or bone marrow transplant) may offer the best chance for a long-term cure. [1] This intensive procedure involves replacing damaged bone marrow with healthy stem cells, though it carries significant risks and is not suitable for every patient. [1]

Figure 3: Overview of treatment strategies ranging from chemoimmunotherapy to advanced CAR T-cell therapy and transplants.

Conclusion and Outlook

Richter transformation is a challenging diagnosis, but advancements in oncology are providing new avenues for treatment. While the condition is aggressive and can be difficult to send into long-term remission, the development of targeted therapies and CAR T-cell treatments is improving life expectancy and quality of life for many. If you are living with CLL and notice sudden changes in your symptoms, contact your oncology team immediately. Early intervention and participation in clinical trials remain the most effective strategies for navigating this complex condition.

---

Frequently Asked Questions

What is the difference between CLL and Richter transformation?

CLL is a slow-growing cancer of the blood and bone marrow, while Richter transformation is the sudden evolution of those cells into an aggressive, fast-growing lymphoma.

How common is Richter transformation?

Richter transformation is a rare complication, affecting approximately 2% to 10% of all people diagnosed with chronic lymphocytic leukemia.

What are the "B symptoms" of lymphoma?

"B symptoms" include persistent fever, drenching night sweats, and unexplained weight loss of more than 10% of body weight over six months.

Can Richter transformation be cured?

While difficult to treat, some patients achieve long-term remission and are considered cured, often through intensive treatments like stem cell transplants.

Is Richter transformation always related to CLL treatment?

No. While it often occurs within the first few years of CLL treatment, it can happen at any time and may even involve lymphoma cells genetically unrelated to the original CLL.

What is the life expectancy for Richter syndrome?

Prognosis varies widely. Life expectancy frequently ranges from several months to a few years, and new therapies are steadily improving these outcomes.

What is CAR T-cell therapy?

CAR T-cell therapy is an advanced immunotherapy where a patient's T-cells are modified in a lab to better recognize and kill cancer cells.

Why are clinical trials recommended for RT?

Because Richter transformation is aggressive and traditional treatments are sometimes ineffective or too toxic, clinical trials offer access to newer, potentially more effective targeted drugs.

Can RT affect the abdomen?

Yes. Patients often experience abdominal pain or bloating, which can be related to swollen lymph nodes or an enlarged spleen or liver.

---

References

1. Cleveland Clinic. Richter Transformation. Cleveland Clinic. November 11, 2025. https://my.clevelandclinic.org/health/diseases/richter-transformation

2. Wang Y, Tschautscher MA, Rabe KG, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105(3):765-773. PMID 31197071. https://doi.org/10.3324/haematol.2019.224121

3. Rippel N, Sheppard R, Kittai AS. Updates in the management of Richter transformation. Cancers. 2024;17(1):95. PMID 39796724. https://doi.org/10.3390/cancers17010095

Medical disclaimer

The information provided in this article is for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.